Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Forecast
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market size reached US$ 5.85 Billion in 2025 and is expected to reach US$ 64.09 Billion by 2033, growing at a CAGR of 35.3% during the forecast period 2026-2033.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Overview
The transthyretin amyloid cardiomyopathy (ATTR-CM) market is witnessing substantial growth, primarily driven by increasing disease awareness, advancements in diagnostic technologies, and the growing availability of novel therapeutics.
Key opportunities in the market include ongoing clinical trials, rising investments in rare disease research, and the expansion of patient access programs, particularly in underserved regions.
North America currently dominates the ATTR-CM market due to early adoption of advanced therapies, robust healthcare infrastructure, and strong presence of key pharmaceutical players. However, the Asia-Pacific region is emerging as the fastest-growing market, supported by rising healthcare expenditure, improving diagnostic capabilities, and growing recognition of amyloidosis-related conditions among clinicians.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market - Executive Summary
Rising prevalence & aging population are significantly driving the transthyretin amyloid cardiomyopathy (ATTR-CM) market growth
The rising prevalence of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a key driver of market growth, fueled by advancements in non-invasive diagnostics and improved patient outcomes. Innovations such as technetium pyrophosphate nuclear cardiac imaging now allow for accurate diagnosis without the need for cardiac biopsy, leading to earlier and broader identification of patients. In the U.S. alone, approximately 5,000 to 7,000 new cases are now diagnosed annually.
Studies indicating a prevalence of around 20% in heart failure patients with myocardial wall thickening over 14 mm highlight the growing clinical awareness and diagnostic precision. Together, these factors are driving demand for effective treatment options and expanding the ATTR-CM therapeutics market.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Key Takeaways
- ATTR-CM is transitioning from an underdiagnosed rare disease into an increasingly recognized and treatable cardiovascular condition.
- Tafamidis, acoramidis and vutrisiran are reshaping the current disease-modifying treatment landscape.
- TTR stabilization and TTR silencing are currently the principal therapeutic approaches, while gene editing and amyloid depletion represent longer-term opportunities.
- Earlier non-invasive diagnosis can substantially expand the treated patient population.
- Genetic testing is increasingly important for differentiating hereditary and wild-type ATTR-CM.
- Administration frequency is becoming a key competitive differentiator, particularly as less-frequent injectable treatments compete with daily oral therapies.
- Treatment selection is increasingly influenced by clinical outcomes, disease stage, patient characteristics, treatment burden and cost.
- High therapy costs remain a major market-access challenge.
- Disease monitoring represents an expanding opportunity as the number of treated patients increases.
- Specialized amyloidosis and cardiology centers can accelerate diagnosis, treatment initiation and long-term monitoring.
- North America remains a major market, while Asia-Pacific offers strong future growth potential.
- The competitive landscape is likely to become more fragmented as next-generation TTR silencers, gene-editing approaches and amyloid-removal therapies advance.
- The largest long-term market opportunity lies in identifying undiagnosed patients and bringing them into appropriate disease-modifying treatment.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Scope
| Metrics | Details | |
| CAGR | 35.3% | |
| Market Size Available for Years | 2023-2033 | |
| Estimation Forecast Period | 2026-2033 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Type | Familial (hereditary) ATTR-CM, Wild-type ATTR-CM |
| Drug Type | Transthyretin Stabilizers, RNAi Therapy, Others | |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Restraint:
High cost of therapy hampering the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) market
The high cost of therapy remains a significant restraint for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market. Current approved treatments, such as tafamidis (Vyndaqel/Vyndamax), can cost over $225,000 annually in markets like the U.S., posing a serious financial burden for patients and healthcare systems. Despite insurance coverage, out-of-pocket expenses can be substantial, limiting access, especially for underinsured or elderly patients on fixed incomes.
Moreover, in many low- and middle-income countries, such therapies are either unavailable or unaffordable, further widening the treatment gap. High costs also strain national healthcare budgets, making widespread reimbursement and adoption of advanced therapies challenging. As new therapies enter the market, pricing pressure and demand for cost-effective alternatives may intensify, but until then, affordability remains a major barrier to equitable access and market penetration.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Opportunity:
Expansion into emerging markets are expected to create a lucrative opportunity for the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) market
Expansion into emerging markets presents a significant opportunity for growth in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market. Many developing countries in regions such as Latin America, Southeast Asia, and parts of the Middle East are experiencing a rapid increase in aging populations, which directly correlates with a higher incidence of ATTR-CM.
Historically, limited diagnostic infrastructure and low disease awareness have hindered detection and treatment in these areas. However, as healthcare systems in these regions modernize, there is increasing investment in rare disease diagnostics, better access to advanced imaging, and improved training for clinicians.
Moreover, pharmaceutical companies are beginning to target these markets with expanded clinical trials, partnerships, and affordable pricing models. By addressing unmet needs and broadening therapeutic availability, expansion into emerging markets not only improves global patient outcomes but also unlocks new revenue streams and drives sustained market growth.
For more details on this report - Request for Sample
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market, Segment Analysis
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market is segmented based on type, drug type, distribution channel, and region.
The transthyretin stabilizers in the drug type segment are expected to hold 54.6% of the market share in 2025 in the transthyretin amyloid cardiomyopathy (ATTR-CM) market
The transthyretin stabilizers segment is expected to dominate the market. This dominance is primarily due to the widespread adoption and clinical success of tafamidis (Vyndaqel/Vyndamax), the first FDA-approved drug for ATTR-CM. Its proven efficacy in reducing all-cause mortality and cardiovascular-related hospitalizations has positioned it as the standard of care.
For instance, in July 2023, BridgeBio Pharma announced positive Phase 3 results from its ATTRibute-CM trial evaluating acoramidis, a next-generation, orally-administered transthyretin stabilizer for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The study confirmed both the efficacy and safety of acoramidis, reinforcing its potential as a powerful therapeutic option. As a highly potent small molecule designed to stabilize transthyretin (TTR), acoramidis represents a significant advancement in ATTR-CM treatment. This development further strengthens the competitive landscape of transthyretin stabilizers and supports the continued market dominance of this therapy class.
Additionally, its oral administration route enhances patient compliance compared to more invasive treatments. Strong backing from clinical trials, increasing physician familiarity, and early diagnosis through advanced imaging have further driven the uptake of stabilizer therapies, reinforcing their leading position in the ATTR-CM market.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market, Geographical Analysis
North America is expected to dominate the global transthyretin amyloid cardiomyopathy (ATTR-CM) market with a 41.2% share in 2025
North America is expected to dominate the transthyretin amyloid cardiomyopathy (ATTR-CM) market, driven by strong clinical research activity, early adoption of advanced therapies, and robust regulatory support. For instance, in February 2024, Ionis Pharmaceuticals and AstraZeneca received Fast Track designation from the U.S. FDA for eplontersen, an investigational RNA-targeted therapy for ATTR-CM, reflecting the region's proactive stance in accelerating drug development for unmet medical needs.
Additionally, in May 2024, BridgeBio Pharma announced positive Phase 3 clinical results for acoramidis during the 2024 International Symposium of Amyloidosis, further underscoring North America’s leadership in ATTR-CM innovation. Coupled with high disease awareness, strong healthcare infrastructure, and favorable reimbursement environments, these advancements solidify North America’s position as the dominant regional market for ATTR-CM therapies.
Asia-Pacific is growing at the fastest pace in the transthyretin amyloid cardiomyopathy (ATTR-CM) market, holding 18.6% of the market share
Asia-Pacific is emerging as the fastest-growing region in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market due to a combination of rising disease awareness, improving diagnostic capabilities, and increasing investments in rare disease treatment. Countries such as Japan, China, and South Korea are witnessing a growing elderly population, creating a larger at-risk patient pool.
Collaborations with local healthcare providers and favorable regulatory reforms aimed at expediting drug approvals are further accelerating the adoption of ATTR-CM therapies in the region. These factors collectively contribute to the region's rapid market expansion and position Asia-Pacific as the fastest-growing market for ATTR-CM treatment.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Trends & Insights
ATTR-CM Diagnosis Is Moving Toward Earlier Non-Invasive Detection
The increasing use of non-invasive cardiac imaging is improving identification of ATTR-CM patients who may previously have been classified as having other forms of heart failure. Bone-avid tracer scintigraphy, combined with appropriate laboratory testing, has become an important component of the diagnostic pathway and can reduce reliance on invasive biopsy in appropriate patients.
The Treatment Landscape Is Expanding Beyond TTR Stabilization
The ATTR-CM market is shifting from a concentrated therapeutic landscape toward multiple disease-modifying mechanisms. TTR stabilizers such as tafamidis and acoramidis are being complemented by TTR-silencing approaches such as vutrisiran, creating greater competition around efficacy, administration frequency, patient selection and long-term outcomes.
RNA Interference Therapy Is Reshaping the Competitive Landscape
RNAi therapies reduce the production of transthyretin rather than stabilizing circulating TTR. The expansion of this approach into ATTR-CM is creating a major alternative to traditional stabilizer therapy and increasing competition around dosing frequency, administration route and clinical outcomes.
Oral Administration Remains a Major Differentiator
Oral therapies provide convenience and may support long-term adherence compared with therapies requiring injections or infusions. Administration frequency is therefore becoming an important factor in treatment selection and commercial positioning.
Long-Acting Treatment Is Gaining Importance
Less frequent administration is becoming increasingly attractive in chronic ATTR-CM management. Therapies administered every few months may reduce treatment burden compared with daily regimens and could improve persistence in appropriately selected patients.
Disease Awareness Is Expanding the Diagnosed Patient Pool
ATTR-CM has historically been underdiagnosed because symptoms can overlap with common forms of heart failure. Increasing awareness among cardiologists, amyloidosis specialists and imaging professionals is expanding screening of patients with unexplained ventricular wall thickening, heart failure with preserved ejection fraction and other clinical indicators.
Aging Populations Are Increasing the Addressable Population
Wild-type ATTR-CM is strongly associated with older populations. Growth in the elderly population, improved survival and increased recognition of age-associated cardiac amyloidosis are supporting expansion of the potential treatment population.
Genetic Testing Is Increasingly Important
Genetic testing helps distinguish hereditary/variant ATTR from wild-type disease and can support patient management and family-risk assessment. Greater use of genetic testing is therefore contributing to more precise disease classification.
Combination and Sequential Treatment Strategies Are Becoming an Area of Interest
As multiple disease-modifying therapies become available, clinical research is increasingly examining how different mechanisms may be used sequentially or in combination. Treatment sequencing could become an important future market differentiator.
Treatment Competition Is Shifting Toward Clinical Outcomes
With multiple therapies available, competition is increasingly focused on mortality, cardiovascular hospitalization, functional capacity, quality of life, tolerability, administration burden and durability of response rather than simply mechanism of action.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Pipeline Analysis
TTR Stabilizers
Future development is focused on improving potency, pharmacological characteristics, dosing convenience and clinical outcomes.
RNAi Therapies
Pipeline programs are evaluating longer-lasting TTR suppression and potentially broader use across ATTR manifestations.
Antisense Oligonucleotides
ASO-based approaches represent another strategy for reducing TTR production.
Gene Editing
Gene-editing candidates are being investigated for potentially durable reduction of TTR production.
Amyloid Depletion
An emerging therapeutic concept involves removing existing amyloid deposits rather than only preventing additional TTR production or stabilization.
Future Market Insight
The next stage of ATTR-CM competition is likely to involve three broad approaches: stabilizing TTR, reducing TTR production and removing existing amyloid deposits.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Competitive Landscape
Top companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) market include Pfizer Inc., Ionis Pharmaceuticals, Inc., among others.
key Developments in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market
- August 2026: Ionis Pharmaceuticals, Inc. announced results from the Phase 3 CARDIO-TTRansform study of eplontersen in ATTR-CM. The trial did not meet its primary endpoint, representing a major setback for the investigational therapy in the ATTR-CM market.
- July 2026: Ionis Pharmaceuticals and AstraZeneca reported that eplontersen failed to demonstrate a statistically significant reduction in cardiovascular mortality and recurrent cardiovascular events in the Phase 3 ATTR-CM study, reducing expectations for expansion of Wainua into ATTR-CM.
- July 2026: Pfizer Inc. benefited from the changing competitive landscape following the eplontersen trial outcome, with its established tafamidis franchise remaining a leading treatment option for ATTR-CM.
- April 2026: Pfizer Inc. reached settlements with three generic-drug manufacturers concerning patent litigation for Vyndamax (tafamidis). The agreements are expected to maintain U.S. patent protection for Vyndamax until June 1, 2031, strengthening the commercial outlook for Pfizer's ATTR-CM franchise.
- May 2026: Ionis Pharmaceuticals continued advancing the CARDIO-TTRansform program, which enrolled 1,432 patients across 130 sites in 20 countries, making it one of the largest ATTR-CM clinical trials conducted to date.
- April 2026: Pfizer Inc. continued strengthening awareness and earlier recognition of ATTR-CM, emphasizing improved diagnosis and identification of patients who may otherwise remain undiagnosed or misdiagnosed.
- 2026: Pfizer Inc. continued focusing on its tafamidis-based ATTR-CM portfolio, with Vyndaqel and Vyndamax remaining important therapies in the treatment landscape.
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market report delivers a detailed analysis with 60+ key tables, more than 55+ visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.
Why Choose DataM?
Technological Innovations: DataM evaluates advances in non-invasive cardiac imaging, genetic testing, RNA interference, TTR stabilization, gene silencing, gene editing, biomarker monitoring and emerging amyloid-depletion technologies.
Product Performance & Market Positioning: The report evaluates ATTR-CM therapies based on mortality outcomes, cardiovascular hospitalization, functional capacity, quality of life, TTR stabilization or suppression, dosing frequency, administration route, safety and treatment convenience.
Real-World Evidence: DataM connects market developments with wild-type and hereditary ATTR-CM, heart failure populations, diagnostic pathways, specialized amyloidosis centers and long-term disease monitoring.
Market Updates & Industry Changes: The report tracks drug approvals, clinical-trial developments, regulatory milestones, diagnostic advances, reimbursement changes, patient-access programs, pipeline therapies and emerging treatment mechanisms.
Competitive Strategies: DataM analyzes how pharmaceutical and biotechnology companies compete through novel mechanisms, differentiated dosing schedules, clinical partnerships, regulatory strategies, patient-support programs and geographic expansion.
Pricing & Market Access: DataM evaluates treatment economics based on therapy type, dosing frequency, administration route, treatment duration, reimbursement conditions, patient assistance programs and regional healthcare-system characteristics.
Market Entry & Expansion: DataM identifies opportunities created by earlier diagnosis, expanding genetic testing, aging populations, improved cardiac imaging, specialist-center development and increasing access to advanced ATTR-CM therapies.
Target Audience
- Pharmaceutical & Biotech Companies - Drug development and market strategy.
- Cardiology & Specialty Centers - Diagnosis and treatment planning.
- Diagnostic Companies - Imaging and genetic-testing opportunities.
- Investors - Market and pipeline intelligence.
- Healthcare Payers - Pricing and reimbursement analysis.
- Research Organizations - ATTR-CM clinical and therapeutic trends.
